Skip to main content

Table 1 Clinical characteristics at baseline and activity of rheumatoid arthritis before and after therapy

From: The balance between Foxp3 and Ror-γt expression in peripheral blood is altered by tocilizumab and abatacept in patients with rheumatoid arthritis

Patient characteristics Abatacept group Tocilizumab group
Number of patients 10 10
Age; yr, mean ± SD 59.8 ± 15.4 57.0 ± 14.0
Female, n (%) 8 (80) 7 (70)
RF positive, n (%) 9 (90) 9 (90)
Anti-CCP Ab positive, n (%) 9 (90) 9 (90)
CRP, mg/dl 2.7 ± 2.1 2.9 ± 3.0
MTX, n (%) 3 (30) 4 (40)
MTX dose, mg/week 10.7 ± 3.1 7.0 ± 2.6
Glucocorticoid, n (%) 9 (90) 3 (30)
Glucocorticoid dose, mg/day 6.3 ± 5.4 6.5 ± 4.1
Previous Biologics, n (%) 6 (60) 6 (60)
Infliximab, n (%) 1 (10)  
Etanercept, n (%) 4 (40) 3 (30)
Adalimumab, n (%) 2 (20) 1 (10)
Abatacept, n (%)   2 (20)
DAS28CRP, mean ± SD   
Before 3.91 ± 1.00  
After 24 weeks 2.74 ± 1.00  
CDAI, mean ± SD   
Before   16.5 ± 7.1
After 24 weeks   6.5 ± 5.3
  1. CCP Cyclic citrullinated peptide, CDAI Clinical Disease Activity Index, CRP C-reactive protein, DAS28 Disease Activity Score for 28 joints, MTX Methotrexate, RF Rheumatoid factor